|Day Low/High||111.67 / 114.41|
|52 Wk Low/High||78.90 / 116.47|
At a London conference, these two U.S. companies get some attention.
Kindred Biosciences stock has more than doubled since it started trading in December, but the company's employees are hard at work developing its osteoarthritis drug.
Solid yielders like these should provide some much-needed cushion in the coming days.
Newly spun-off from Pfizer, Zoetis has big plans for its animal health business in the emerging markets, says the company's CEO Juan Ramon Alaix.
These name capitalize on the trend of spending on our pets, which has become recession proof.
Investors should track companies with solid earnings growth, but avoid speculative ventures.
The January jobs report helps the Dow Jones Industrial Average cross 14,000.
Pfizer strips down Zoetis, but institutional buyers love it says IPO Desktop President Francis Gaskins.